Several animal models of schizophrenia and patients with chronic schizophrenia have shown increased spontaneous power of gamma oscillations. However, the most robust alterations of gamma oscillations in patients with schizophrenia are reduced auditory–oscillatory responses. We hypothesized that patients with early-stage schizophrenia would have increased spontaneous power of gamma oscillations and reduced auditory–oscillatory responses. This study included 77 participants, including 27 ultra-high-risk (UHR) individuals, 19 patients with recent-onset schizophrenia (ROS), and 31 healthy controls (HCs). The auditory steady-state response (ASSR) and spontaneous power of gamma oscillations measured as induced power during the ASSR period were calculated using electroencephalography during 40-Hz auditory click-trains. The ASSRs were lower in the UHR and ROS groups than in the HC group, whereas the spontaneous power of gamma oscillations in the UHR and ROS groups did not significantly differ from power in the HC group. Both early-latency (0–100 ms) and late-latency (300–400 ms) ASSRs were significantly reduced and negatively correlated with the spontaneous power of gamma oscillations in the ROS group. In contrast, UHR individuals exhibited reduced late-latency ASSR and a correlation between the unchanged early-latency ASSR and the spontaneous power of gamma oscillations. ASSR was positively correlated with the hallucinatory behavior score in the ROS group. Correlation patterns between the ASSR and spontaneous power of gamma oscillations differed between the UHR and ROS groups, suggesting that the neural dynamics involved in non-stimulus-locked/task modulation change with disease progression and may be disrupted after psychosis onset.
2 May 2016 in Psychiatry and Clinical Neurosciences
Aim: Go/No‐go derived event‐related potential (ERP) signals have been widely used in schizophrenia research to monitor self‐control deficits in this disorder. However, no study to date has associated Go/No‐go‐related ERP with global functioning.Methods: Participants consisted of 21 patients with schizophrenia and 22 healthy controls. We used a visual Go/No‐go paradigm to measure Go/No‐go‐related N2/P3 ERP components by means of a 64‐electrode cap for electroencephalogram recording. We used the Global Assessment of Functioning to evaluate global functioning and analyzed the correlation between ERP indices and global functioning scores.Results: N2 amplitudes were reduced in patients with schizophrenia, but not influenced by either of the Go/No‐go conditions. P3 amplitudes were influenced by the Go/No‐go conditions, but not reduced in patients with schizophrenia. Global functioning was correlated with the No‐go P3 amplitudes, but not N2 amplitudes, in patients with schizophrenia.Conclusion: These results indicate that global functioning is associated with intact neural activity rather than impaired neural activity during Go/No‐go response inhibition tasks in patients with schizophrenia.
Organizations are plagued by sophisticated and diversified cyber attacks. In order to prevent such attacks, it is necessary to understand threat trends and to take measures to protect their assets. Security vendors publish reports which contain threat trends or analysis of malware. These reports are useful for help in responding to a cyber security incident. However, it is difficult to collect threat information from multiple sources such as security blog posts. In this paper, we propose a method to efficiently collect information from the relationship between words using SeededLDA. In our case studies, we visualize the relationship between the words from security blog posts which were published in 2017 by eight security vendors, and demonstrate how our method helps to understand threat trends in the IoT industry and financial institutions.
The purpose of this study is to evaluate the efficacy of annual zoledronic acid treatment in Japanese patients with nonmetastatic prostate cancer during androgen deprivation therapy (ADT). This is a single institution 12-month study. Between 2016 and 2019, patients aged 70 years or older on ADT for nonmetastatic prostate cancer had bone mineral density (BMD) measured and 10-year probability of fracture calculated using fracture risk assessment tool (FRAX). Patients who showed osteopenia or had a 10-year hip fracture risk ≥ 3% or a 10-year probability of major osteoporotic fracture ≥ 20% were offered treatment with zoledronic acid 5 mg intravenously (ZA group). The patients who did not receive treatment were set as the control group. Lumbar and hip BMD were measured 6 and 12 months after treatment in the ZA group and 12 months after baseline in the control group. The yearly BMD change of both groups was compared. The mean ages of the ZA group (n = 26) and control group (n = 12) were 80.5 ± 9.1 and 76.1 ± 6.7 years, respectively. In the ZA group, lumbar and hip BMD changes at 12 months were +2.1% and +0.8%, respectively. In the control group, lumbar and hip BMD changes were -0.9% and -4.9%, respectively. There were statistically significant differences between the 2 groups in BMD percent changes (P < 0.05). Without intervention, BMD tends to continue to decrease during ADT. Our findings suggest that administration of zoledronic acid enables maintenance of BMD in the older adults.